← Back to Search

Dual-Tracer PET Scans for Prostate Cancer

N/A
Waitlist Available
Led By Jeffrey A Yap, PhD
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 days
Awards & highlights
No Placebo-Only Group

Summary

This trial tests new imaging techniques to help understand diseases better.

Who is the study for?
Adults with measurable prostate cancer or neuroendocrine tumors, willing to undergo PET/CT scans and have their records reviewed for 24 months. Women of childbearing potential must test negative for pregnancy. Exclusions include exceeding weight limits, recent participation in other clinical studies, known allergies to study materials, and claustrophobia.
What is being tested?
The trial is testing four different single-tracer PET/CT exams (FDG, Cu64-DOTATATE, Ga68-DOTATATE, PSMA) on patients with prostate cancer or neuroendocrine tumors. The goal is to gather data for developing dual-tracer imaging techniques.
What are the potential side effects?
Potential side effects may include reactions to the tracers used during the PET/CT exams such as allergic reactions or hypersensitivity. Discomfort from lying flat during scanning could also occur.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Completion of two PET/CT scans per patient as dictated by assigned arm

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Arm 3Experimental Treatment2 Interventions
Single-Tracer FDG PET/CT exam + Single-Tracer PSMA (prostate-specific membrane antigen) PET/CT exam
Group II: Arm 2Experimental Treatment2 Interventions
Single-Tracer FDG PET/CT exam + Single-Tracer Ga68-DOTATATE PET/CT exam
Group III: Arm 1Experimental Treatment2 Interventions
Single-Tracer FDG (F18 Fluorodeoxyglucose) PET/CT exam + Single-Tracer Cu64-DOTATATE PET/CT
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Single-Tracer PSMA PET/CT Exam
2022
N/A
~50
Single-Tracer FDG PET/CT Exam
2022
N/A
~50
Single-Tracer Ga68-DOTATATE PET/CT Exam
2022
N/A
~50
Single-Tracer Cu64-DOTATATE PET/CT Exam
2022
N/A
~50

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,139 Previous Clinical Trials
1,697,310 Total Patients Enrolled
2 Trials studying Neuroendocrine Tumors
3,016 Patients Enrolled for Neuroendocrine Tumors
MultiFunctional Imaging LLCUNKNOWN
National Cancer Institute (NCI)NIH
13,917 Previous Clinical Trials
41,014,403 Total Patients Enrolled
81 Trials studying Neuroendocrine Tumors
43,723 Patients Enrolled for Neuroendocrine Tumors

Media Library

Arm 1 Clinical Trial Eligibility Overview. Trial Name: NCT05680675 — N/A
Neuroendocrine Tumors Research Study Groups: Arm 1, Arm 2, Arm 3
Neuroendocrine Tumors Clinical Trial 2023: Arm 1 Highlights & Side Effects. Trial Name: NCT05680675 — N/A
Arm 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT05680675 — N/A
~17 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top